0001127602-23-029691.txt : 20231215
0001127602-23-029691.hdr.sgml : 20231215
20231215160449
ACCESSION NUMBER: 0001127602-23-029691
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20231214
FILED AS OF DATE: 20231215
DATE AS OF CHANGE: 20231215
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Dunlop A. Sinclair
CENTRAL INDEX KEY: 0001721108
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38276
FILM NUMBER: 231490265
MAIL ADDRESS:
STREET 1: C/O APELLIS PHARMACEUTICALS, INC.
STREET 2: 6400 WESTWIND WAY, SUITE A
CITY: CRESTWOOD
STATE: KY
ZIP: 40014
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Apellis Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001492422
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 271537290
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 100 FIFTH AVENUE
CITY: WALTHAM
STATE: MA
ZIP: 02451
BUSINESS PHONE: 617-977-5700
MAIL ADDRESS:
STREET 1: 100 FIFTH AVENUE
CITY: WALTHAM
STATE: MA
ZIP: 02451
4
1
form4.xml
PRIMARY DOCUMENT
X0508
4
2023-12-14
0001492422
Apellis Pharmaceuticals, Inc.
APLS
0001721108
Dunlop A. Sinclair
C/O APELLIS PHARMACEUTICALS, INC.
100 FIFTH AVENUE, 3RD FLOOR
WALTHAM
MA
02451
1
0
Common Stock
2023-12-14
4
M
0
6274
13.19
A
128677
D
Common Stock
192679
I
Indirect Owner (Epidarex)
Common Stock
31855
I
Indirect Owner (Masa)
Stock Option (Right to Buy)
13.19
2023-12-14
4
M
0
6274
0
D
2028-12-31
Common Stock
6274
7000
D
The securities are held by Epidarex and the reporting person, a general partner of Epidarex, may be deemed to have voting and dispositive power over the shares held by Epidarex. The reporting person disclaims beneficial ownership over the shares held by Epidarex except to the extent of his pecuniary interest therein.
The securities are held by MASA and the reporting person, a managing partner of MASA, may be deemed to have voting and dispositive power over the shares held by MASA. The reporting person disclaims beneficial ownership over the shares held by MASA except to the extent of his pecuniary interest therein.
This option was granted on January 1, 2019 and fully vested.
/s/ David Watson, attorney-in-fact for Sinclair Dunlop
2023-12-15